• 1
    Melnyk A, Rodriguez A, Pugh WC, et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997; 89: 4514-4520.
  • 2
    Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998; 92: 76-82.
  • 3
    Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998; 9: 849-855.
  • 4
    Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004; 103: 2474-2479.
  • 5
    Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003; 102: 4261-4269.
  • 6
    Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; 15: 1467-1475.
  • 7
    Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005; 19: 2186-2194.
  • 8
    ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000; 53: 445-450; comment 2000;53:407-408, 2001;54:494-495.
  • 9
    Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999; 93: 3913-3921.
  • 10
    Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999; 93: 2697-2706.
  • 11
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333: 1540-1545; comment 1995;333:1565-1566.
  • 12
    Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003; 120: 978-985.
  • 13
    Jagasia M, Morgan D, Goodman S, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma. 2004; 45: 2261-2267.
  • 14
    Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006; 134: 202-207.
  • 15
    Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007; 21: 201-216.
  • 16
    Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000; 96: 2943-2950.
  • 17
    Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002; 99: 4525-4530.
  • 18
    Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007; 67: 746-755.
  • 19
    Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999; 163: 380-386.
  • 20
    Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001; 98: 210-216; comment 2001;98:3495-3496.
  • 21
    Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006; 108: 618-621.
  • 22
    Lin YC, Shun CT, Wu MS, et al. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res. 2006; 12: 7165-7173.
  • 23
    Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15: 1950-1961.
  • 24
    Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005; 69: 56-63.
  • 25
    Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003; 17: 41-44.
  • 26
    Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006; 24: 5343-5349.
  • 27
    Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357: 2133-2142; comment Nat Clin Pract Oncol. 2008; 5: 372-373,N Engl J Med. 2007; 357: 2183-2186.
  • 28
    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465; comment Nat Clin Pract Oncol. 2007;4:396-397.
  • 29
    Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111: 86-93.
  • 30
    Querfeld C, Kuzel TM, Guitart J, et al. Preliminary results of a phase II study of CC-5013 (lenalidomide, Revlimid(R)) in patients with cutaneous T-cell lymphoma [abstract]. ASH Annual Meeting Abstracts. 2005; 106: 3351.
  • 31
    Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26: 4952-4957.
  • 32
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244; erratum 2000;18:2351.
  • 33
    Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001; 113: 185-187.
  • 34
    Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998; 9: 1351-1353; comment 1998;9:1265-1267.
  • 35
    Piekarz R, Frye R, Wright J, et al. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma ASCO Annual Meeting Proceedings pt I. J Clin Oncol. 2007; 25: 8027.
  • 36
    Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007; 136: 439-447.
  • 37
    Sviggum HP, Davis MD, Rajkumar SV, et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006; 142: 1298-1302.
  • 38
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549-557; comment Nat Clin Pract Oncol. 2005;2:390-391, N Engl J Med. 2005;352:536-538, N Engl J Med. 2005;352:2134-2135; author reply 2005;352:2134-2135.
  • 39
    Revlimid Product Monograph. Summit, NJ: Celgene Corporation; 2008.
  • 40
    Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in 2 large phase III studies. Clin Cancer Res. 2007; 13: 3913-3921.
  • 41
    Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357: 2040-2048; comment N Engl J Med. 2008;358:1195; author reply 1196-1197, N Engl J Med. 2008;358:1196; author reply 1196-1197, Nat Clin Pract Oncol. 2008;5:310-311, ACP J Club.2008;148:8.
  • 42
    Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol. 2007; 25: 4459-4465.
  • 43
    Wang M, Fayad L, Hagemeister F, et al. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. ASCO Annual Meeting Proceedings pt I. J Clin Oncol. 2007; 25: 8030.